Becton Dickinson and Co (BDX)

Currency in USD
201.91
-1.57(-0.77%)
Closed·
203.59+1.68(+0.83%)
·
Earnings results expected in 6 days
BDX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
201.19203.61
52 wk Range
162.29246.75
Key Statistics
Prev. Close
203.48
Open
203
Day's Range
201.19-203.61
52 wk Range
162.29-246.75
Volume
1.95M
Average Volume (3m)
2.18M
1-Year Change
-18.4564%
Book Value / Share
88.58
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BDX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
207.92
Upside
+2.97%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 55 consecutive years

Becton Dickinson and Co News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Becton Dickinson Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton Dickinson and Co SWOT Analysis


Strategic Separation
Explore Becton Dickinson's bold move to separate its Life Sciences division, potentially unlocking significant value and reshaping its market position.
Financial Resilience
Delve into BDX's robust financial performance, exceeding market expectations despite stock underperformance and trading near 52-week lows.
Valuation Puzzle
Uncover the intriguing valuation gap of BDX, trading below historical averages with analyst targets ranging from $185 to $280.
Future Growth Catalysts
Learn how BDX's strategic initiatives and industry positioning could drive multiple expansion and long-term shareholder value in the medical technology sector.
Read full SWOT analysis

Becton Dickinson and Co Earnings Call Summary for Q4/2025

  • Becton Dickinson reported Q4 EPS of $3.96, beating expectations by 1.02%, while revenue slightly missed at $5.9 billion; stock dropped 7.59% to $163 in premarket trading.
  • Full-year revenue increased 7.7% to $21.8 billion with 3.9% organic growth in Q4; the company returned $2.2 billion to shareholders, marking its 54th consecutive year of dividend increases.
  • FY2026 guidance projects EPS between $14.75-$15.05 with low single-digit revenue growth; China expected to see mid-teens decline due to volume-based procurement challenges.
  • CEO Tom Polen expressed confidence in long-term mid-single-digit growth profile despite anticipated 25% decline in vaccine revenue and macroeconomic pressures in global markets.
Last Updated: 06/11/2025, 14:28
Read Full Transcript

Compare BDX to Peers and Sector

Metrics to compare
BDX
Peers
Sector
Relationship
P/E Ratio
34.3x26.3x−0.6x
PEG Ratio
−50.610.620.00
Price/Book
2.3x2.6x2.6x
Price / LTM Sales
2.6x2.9x3.4x
Upside (Analyst Target)
2.5%15.7%44.9%
Fair Value Upside
Unlock19.1%6.3%Unlock

Analyst Ratings

5 Buy
9 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 207.92
(+2.97% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Hold205.00+1.53%190.00Maintain28/01/2026
Stifel
Buy215.00+6.48%210.00Maintain07/01/2026
RBC Capital
Hold210.00+4.01%202.00Maintain17/12/2025
Jefferies
Buy220.00+8.96%215.00Maintain10/12/2025
Morgan Stanley
Buy210.00+4.01%197.00Maintain02/12/2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.82%
Dividend Yield
2.08%
Industry Median 1.33%
Annualised payout
4.20
Paid quarterly
5-Years Growth
+5.65%
Growth Streak

Earnings

Latest Release
Nov 06, 2025
EPS / Forecast
3.96 / 3.92
Revenue / Forecast
5.90B / 5.91B
EPS Revisions
Last 90 days

People Also Watch

271.54
CI
-0.94%
99.50
KMB
-0.49%
40.14
DVN
-0.17%
108.41
EOG
-3.32%
27.81
CTRA
-3.60%

FAQ

What Is the Becton Dickinson (BDX) Share Price Today?

The live Becton Dickinson share price today is 201.91

What Stock Exchange Does Becton Dickinson (BDX) Trade On?

Becton Dickinson is listed and trades on the New York Stock Exchange.

What Is the Ticker (Stock Symbol) for Becton Dickinson?

The stock symbol (also called a 'ticker') for Becton Dickinson is "BDX."

Does Becton Dickinson Pay Dividends? What’s The Current BDX Dividend Yield?

Yes, BDX Pays Dividends to its Shareholders. The current Becton Dickinson dividend yield is 2.08%.

What Is the Current Becton Dickinson Market Cap?

As of today, Becton Dickinson market capitalisation is 57.53B.

What Is Becton Dickinson's (BDX) Earnings Per Share (TTM)?

The Becton Dickinson EPS is currently 5.82 (Trailing Twelve Months).

When Is the Next Becton Dickinson Earnings Date?

Becton Dickinson's next earnings report will be released on 09 Feb 2026.

Is BDX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Becton Dickinson moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Becton Dickinson Stock Split?

Becton Dickinson has split 5 times. (See the BDX stock split history page for full effective split date and price information.)

How Many Employees Does Becton Dickinson Have?

Becton Dickinson has 72000 employees.

What is the current trading status of Becton Dickinson (BDX)?

As of 03 Feb 2026, Becton Dickinson (BDX) is trading at a price of 201.91, with a previous close of 203.48. The stock has fluctuated within a day range of 201.19 to 203.61, while its 52-week range spans from 162.29 to 246.75.

What Is Becton Dickinson (BDX) Price Target According to Analysts?

The average 12-month price target for Becton Dickinson is USD207.92, with a high estimate of USD270 and a low estimate of USD183. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +2.97% Upside potential.

What Is the BDX Premarket Price?

BDX's last pre-market stock price is 201.30. The pre-market share volume is 780.00, and the stock has decreased by -2.18, or -1.07%.

What Is the BDX After Hours Price?

BDX's last after hours stock price is 203.59, the stock has decreased by 1.68, or 0.83%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.